Manufacturers Life Insurance Company Increases Investment in Caris Life Sciences

The Manufacturers Life Insurance Company announced a significant 50.8% increase in its investment in Caris Life Sciences, Inc. during the first quarter, according to its recent 13F filing with the Securities and Exchange Commission (SEC). This acquisition elevates the company's holdings to 153,512 shares, valued at approximately $2.745 million and accounting for 0.05% of Caris Life Sciences. This move underscores the company's strategic investment focus within the biotech sector.

Other investors, such as Sumitomo Mitsui Trust Group Inc., have also adjusted their positions, expanding holdings by 26.5% in the fourth quarter to 75,330 shares valued at $2.032 million. Notable new entrants to Caris Life Sciences' shareholder list include Oak Ridge Investments LLC and Mirae Asset Global Investments Co. Ltd., while GF Fund Management Co. Ltd. and TD Waterhouse Canada Inc. have also increased their stakes.

Recent insider trading activity includes Director Jeff L. Vacirca's acquisition of 31,050 shares at $16.15 each, totaling $501,457.50, boosting his direct ownership to 49,671 shares. Similarly, Director Jon Halbert purchased 68,000 shares at a price of $14.56, costing $990,080, which raises his holdings to 704,598 shares. These transactions are detailed in filings with the SEC.

Analyst ratings reveal diverse outlooks, with Weiss Ratings upgrading Caris Life Sciences and Robert W. Baird establishing a price target of $22. Despite BTIG Research increasing its target price to $33 with a "buy" rating, Wall Street Zen has taken a more cautious stance. Current consensus among analysts, as cited by MarketBeat, points to a "Moderate Buy" rating, with an average target price of $26.33.

Caris Life Sciences recently traded at $22.74 with a 12-month low of $14.19 and a high of $42.50. With a market cap of $6.43 billion and a price-to-earnings ratio of 63.17, the company exhibits a beta of 0.68. Financially, it remains robust with a quick ratio of 6.52 and a current ratio of 5.53. The Board's $100 million share repurchase authorization suggests potential undervaluation. Specializing in precision oncology, Caris Life Sciences leverages molecular profiling and high-throughput sequencing to enhance treatment decisions and patient care.

For further insights into holdings and insider trading, HoldingsChannel.com provides comprehensive data.